HARVESTING OF VALUABLE ENO- AND EXO-METABOLITES FORM CYANOBACTERIA: A POTENTIAL SOURCE

  • Maheep Kumar Guru Ghasidas Vishwavidylaya

Abstract

Most of the disease is growing resistace from thr applied drugs. However, in this view people search for cheap and effective drugs for their cure. Cyanobacteria in this respect can help in curing disease with cheap and effective manner. Cyanobacteria are photosynthetic prokaryotic microorganism. From ancient time cyanobacteria were used as food and fodder. However, it is notorious for toxin production and fouling of ponds as it form water bloom. Now-a-days various studies have done to prove its potency in medical science also. They produce various metabolites that are antibacterial, antifungal, antimalarial, anticancerous, antitumor, antialgal, antiviral, UV protectants, inhibitors of enzymes, hepatotoxins and neurotoxins. These metabolites produced at the particular cell age and are regulated by various biotic and abiotic factors. Many cyanobacteria produce compounds with potent biological activities.This review aims to showcase of cyanobacterial secondary metabolites with a comprehensive coverage of antibacterial, antifungal and other activity of cyanobacteria.

Author Biography

Maheep Kumar, Guru Ghasidas Vishwavidylaya

Department of Botany

Assistant Professor (Ad-hoc)

References

1. Harvey AL Natural products in drug discovery. Drug Discovery Today 2008; 19/20(13): 894-901.

2. Reynolds R, Potz N, Colman M, Williams A, Livermore D, MacGowan A. Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC bacteraemia resistance surveillance programme. Journal of Antimicrobial Chemotherapy 2004; 53: 1018-1032.

3. Karchmer AW. Increased antibiotic resistance in respiratory tract pathogens: PROTEKT US- an update. Clinical Infectious Disease 2004; 39: 142-150.

4. Paterson DL. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clinical Infectious Disease 2006; 43: 43-48.

5. Cowan DA. Microbial genomes: the untapped resource. Trends in Biotechnology 2000; 18: 14-16.

6. Clardy J, Fischbach MA, Walsh CT. New antibiotics from bacterial natural products. Natural Biotechnology 2006; 24: 1541–1550.

7. Kumar M, Tripathi MK, Srivastava A, Nath G, Asthana RK. A Comparative Study of Antibacterial Activity of Brackish and Fresh Water Cyanobacterial Strains. Asian Journal of Experimental Biological Sciences 2012; 3(3):548-552.

8. Kumar M, Tripathi MK, Srivastava A, Gour JK, Singh RK, Tilak R, Asthana RK. Cyanobacteria, Lyngbya aestuarii and Aphanothece bullosa as antifungal and antileishmanial drug resources. Asian Pacific Journal of Tropical Biomedicine 2013; 3(6): 458-463.

9. Kumar M. Lyngbya sp. : a suitable cyanobacterium for harvesting antimicrobial compounds. Asian Journal of Pharmaceutical Clinical Reseasrch 2014; 7(1): 6-9.

10. Han B, McPhail KL, Gross H, Goeger DE, Mooberry SL, GerwickWH. Isolation and structure of five lyngbyabellin derivatives from a Papua New Guinea collection of the marine cyanobacterium Lyngbya majuscula, Tetrahedron 2005; 61: 11723-11729.

11. Berry JP, Gantar M, Gawley RE, Wang M, Rein KS. Pharmacology and toxicology of pahayokolide A, a bioactive metabolite from a freshwater species of Lyngbya isolated from the Florida Everglades. Comparative Biochemisty & Physiology 2004; 139: 231–238.

12. Mayer AMS, Rodriguez AD, Berlinck RGS, Hamann MT Marine phar- macology in 2005–6: Marine compounds with anthelmintic, antibacterial, anticoagulant, antifungal, anti-inflammatory, antimalarial, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems, and other misce- llaneous mechanisms of action. Biochimica Biophysica Acta 2009; 1790: 283-308.

13. Linington RG, Clark BR, Trimble EE, Almanza A, Ureña LD, Kyle DE, Gerwick WH Antimalarial peptides from marine cyanobacteria: isolation and structural elucidation of gallinamide A. Journal of Natural Product 2009; 72: 14-17.

14. McPhail KL, Correa J, Linington RG, González J, Ortega-Barría E, Capson TL, Gerwick WH. Antimalarial linear lipopeptides from a Panamanian strain of marine cyanobacterium Lygbya majuscule. Journal of Natural Product 2007; 70: 984-988.

15. Sivonen K. Effects of Light, Temperature, Nitrate, Orthophosphate, and Bacteria on Growth of and Hepatotoxin Production by Oscillatoria agardhii Strains. Appl Environ Microbiol 1990; 2658-2666.

16. Granéli E, Flynn K. Chemical and Physical Factors Influencing Toxin Content. Ecological Study 2006; 189: 229-241.

17. Østensvik Ø, Skulberg OM, Underdal B, Hormazabal V. Antibacterial properties of extracts from selected planktonic freshwater cyanobacteria – a comparative study of bacterial bioassays. Journal of Applied Microbiology 1998; 84, 1117–1124.

18. Ghasemi Y, Moradian A, Mohagheghzadeh A, Shokravi S, Morowvat MH Antifungal and antibacterial activity of microalgae collected from paddy field of Iran: characterization of antimicrobial activity of Chroococcus disperses. Journal of Biological Sciences 2007; 7(6): 904-910.

19. Rao M, Malhotra S, Fatma T, Rattan A. Antimycobacterial activity from cyanobacterial extracts and phytochemical screening of methanol extract of Hapalosiphon. Pharmaceutical Biology 2007;45: 88-93.

20. Drobac-Åik AV, Duliã TI, Stojanoviã DB, Sviråev ZB The importance of extremophile cyanobacteria in the production of biological active compounds. Matica Srpska Proceed. Natural Science Novi Sad 2007;112: 57—66.

21. Pawar ST, Puranik PR. Screening of terrestrial and freshwater halotolerant cyanobacteria from antifungal activities. World J Biotechnol 2008; 24: 1019-1025.

22. Meizoso R, Jaime L, Santoyo S, Cifuentes A, Reina GG-B, Senorans FJ, Ibanez E. Pressurized Fluid Extraction of Bioactive Compounds from Phormidium Species. Journal of Agricultural Food Chemistry 2008; 56: 3517–3523.

23. Dobretsov S, Abed RMM, Al-Maskari SMS, Al-Sabahi JN, Victor R. Cyanobacterial mats from hot springs produce antimicrobial compounds and quorum-sensing inhibitors under natural conditions. Journal of Applied Phycology 2011; 23: 983–993.

24. Madhumathi V, Deepa P, Jeyachandran S, Manoharan C, Vijayakumar S Antimicrobial Activity of Cyanobacteria Isolated from Freshwater Lake. International Journal of Microbiological Research 2011; 2 (3): 213-216.

25. Silva-Stenico ME, Silva CSP, Lorenzi AS, Shishido TK, Etchegaray A, Lira SP, Moraes LAB, Fiore MF. Non-ribosomal peptides produced by Brazilian cyanobacterial isolates with antimicrobial activity. Micorbiological Research 2011;166: 161-175.

26. Prabakaran M. Invitro antimicrobial potentials of marine Oscillatoria species. Asian Journal of Plant Science Research 2011;1 (3): 58-64.

27. Ramamurthy V, Raveendran S, Thirumeni S, Krishnaveni S. Antimicrobial activity of Heterocytic Cyanobacteria. International Journal of Advance Life Science 2012; 1: 32-39.

28. Thummajitsakul S, Silprasit K, Sittipraneed S. Antibacterial activity of crude extracts of cyanobacteria Phormidium and Microcoleus species. African Journal of Microbiological Research 2012; 6(10): 2574-2579.

29. Balunas MJ, Linington RG, Tidgewell K, Fenner AM, Ureña LD, Togna GD, Kyle DE, Gerwick WH. Dragonamide E, a modified linear lipopeptide from Lyngbya majuscula with antileishmanial activity. Journal of Natural Product 2010; 73: 60-66.

30. Nunnery JK, Mevers E, Gerwick WH. Biologically active secondary metabolites from marine Cyanobacteria. Current Opinion in Biotechnology 2010; 21: 787–793.

31. Harada K. Production of Secondary Metabolites by Freshwater Cyanobacteria. Chemical Pharmacology Bulletin 2004; 52(8): 889-899.

31. Sanchez LM, Lopez D, Vesely BA, Della Togna G, Gerwick WH, Kyle DE, Linington RG. Almiramides A-C: discovery and development of a new class of leishmaniasis lead compounds. Journal of Medicinal Chemistry 2010; 53: 4187-4197.

33. Mo S, Krunic A, Chlipala G, Orjala J. Antimicrobial Ambiguine Isonitriles from the Cyanobacterium Fischerella ambigua. Journal of Natural Product 2009; 72: 894–899.

34. Matern U, Oberer L, Erhard M, Herdman M, Weckesser J. Hofmannolin, a cyanopeptolin from Scytonema hofmanni PCC 7110. Phytochemistry 2003; 64: 1061–1067.

35. Zainuddin EN, Jansen R, Nimtz M, Wray V, Preisitsch M, Lalk M, Mundt S. Lyngbyazothrins A-D, Antimicrobial Cyclic Undecapeptides from the Cultured Cyanobacterium Lyngbya sp. Journal of Natural Product 2009; 72: 1373–1378.

36. Wright AD, Papendorf O, Ko¨nig GM. Ambigol C and 2,4-Dichlorobenzoic Acid, Natural Products Produced by the Terrestrial Cyanobacterium Fischerella ambigua. Journal of Natural Product 2005; 68: 459-461.

37. Ploutno A, Carmeli S. Nostocyclyne A, a Novel Antimicrobial Cyclophane from the Cyanobacterium Nostoc sp. Journal of Natural Product 2000; 63: 1524-1526.

38. Simmons TL, Engene N, Uren˜a LD, Romero LI, Ortega-Barrı´a E, Gerwick L, Gerwick WH. Viridamides A and B, Lipodepsipeptides with Antiprotozoal Activity from the Marine Cyanobacterium Oscillatoria nigro-Wiridis. Journal of Natural Product 2008; 71: 1544–1550.

39. Linington RG, Gonza´lez J, Uren˜a L, Romero LI, Ortega-Barrı´a E, Gerwick WH. Venturamides A and B: Antimalarial Constituents of the Panamanian Marine Cyanobacterium Oscillatoria sp. Journal of Natural Product 2007; 70: 397-401.

40. MacMillan JB, Ernst-Russell MA, Jeffrey S, de Ropp, Molinski TF. Lobocyclamides A-C, Lipopeptides from a Cryptic Cyanobacterial Mat Containing Lyngbya confervoides. Journal of Organic Chemistry 2002; 67: 8210-8215.

41. Biondi N, Piccardi R, Margheri MC, Rodolfi L, Smith GD, Tredici MR Evaluation of Nostoc strain ATCC 53789 as a potential source of natural pesticides. Applied Environmental Microbiology 2004; 70: 3313–3320.

42. Gutiérrez RMP, Flores AM, Solı´s RV, Jimenez JC. Two new antibacterial norabietane diterpenoids from cyanobacteria, Microcoleous lacustris. Journal of Natural Medicine 2008; 62: 328–331.

43. Kim H, Lantvit D, Hwang CH, Kroll DJ, Swanson SM, Franzblau SG, Orjala J. Indole alkaloids from two cultured cyanobacteria, Westiellopsis sp. and Fischerella muscicola, Bioorganic Medicinal Chemistry 2012; 20: 5290–5295.

44. Volk RB, Girreserb U, Al-Refaic M, Laatsch H. Bromoanaindolone, a novel antimicrobial exometabolite from the cyanobacterium Anabaena constricta. Natural Product Research 2009;23(7): 607–612.

45. Volk RB, Mundt S. Cytotoxic and non-cytotoxic exometabolites of the cyanobacterium Nostoc insulare. Journal of Applied Phycology 2007; 19: 55-62.

46. Volk RB, Furkert FH. Antialgal, antibacterial and antifungal activity of two metabolites produced and excreted by cyanobacteria during growth. Microbiological Research 2006; 161: 180-186.

47. Sudo H, Grant Burgess J, Takemasa H, Nakamura N, Matsunaga T. Sulfated exopolysaccharide production by the halophilic cyanobacterium Aphanocapsa halophytica. Current Microbiology 1995; 30: 219-222.

48. Falch BS, König GM, Wright AD, Sticher O, Angerhofer CK, Pezzuto JM, Bachmann H Biological activities of cyanobacteria: evaluation of extract and pure compounds. Plant Medicine 1995; 61: 321-328.

49. Jaki B, Orjala J, Sticher O. A novel extracellular diterpenoid with antibacterial activity from the cyanobacterium Nostoc commune. Journal of Natural Product 1999; 62: 502–503.

50. Stratmann K, Moore RE, Bonjouklian R, Deeter JB, Patterson GML, Shaffer S, Smith CD, Smitka TA. Welwitindolinones, unusual alkaloids from the blue-green algae Hapalosiphon welwitschii and Westiella intricata Relationship to fischerindoles and hapalindoles. Journal of American Chemical Society 1994; 116: 9935-9942.

51. Hemscheidt T, Puglisi MP, Larsen LK, Petterson GML, Moore RE, Rios JL, Clardy J. Structure and biosynthesis of borophycin, a new boeseken complex of boric acid from marine strain of the blue-green alga Nostoc linckia. Journal of Organic Chemistry 1994; 59: 3467-3471.

52. Borowitzka MA. Microalgae as sources of pharmaceuticals and other biologically active compounds. Journal of Applied Phycology 1995; 7: 3-15.

53. Runnegar M, Berndt N, Kong SM, Lee EY, Zhang L. In vivo and in vitro binding of microcystin to protein phosphatases 1 and 2A. Biochemistry Biophysics Research Community 1995; 216: 162-169.

54. Orjala J, Gerwick WH. Barbamide, a Chlorinated Metabolite with Molluscicidal Activity from the Caribbean Cyanobacterium Lyngbya majuscule. Journal of Natural Product 1996; 59: 427-430.

55. Boyd MR, Gustafson KR, McMohan JB, Shoemaker RH, O’Keefe BR, Mori T, Gulakowski RJ, Wu L, Rivera MI, Laurencot CM, Currens MJ, Cardellina IJH, Buckheit JRW, Nara PL, Pannell LK, Sowder IRC, Henderson LE Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential application to microbicide development. Antimicrobial Agent Chemotherapy 1997; 41: 1521-1530.

56. Sano T, He J, Liu Y, Kaya K. Isolation of bioactive compounds in cyanobacteria from Chinese fresh water: 1.
Trypsin inhibitor. Physiological Research 1998; 46: 13-17.

57. Singh IP, Milligan KE, Gerwick WH. Tanikolide, a Toxic and Antifungal Lactone from the Marine Cyanobacterium Lyngbya majuscule. Journal of Natural Product 1999; 62: 1333-1335.

58. Hirata K, Takashina J, Nakagami H, Ueyama S, Murakami K, Kanamori T, Miyamoto K. Growth inhibition of various organisms by a violet pigment, nostocine A, produced by Nostoc spongiaeforme. Bioscience Biotechnology Biochemistry 1996; 66: 1905–1906.

59. Becher PG, Beuchat J, Gademann K, Jüttner F Nostocarboline: isolation and synthesis of a new cholinesterase inhibitor from Nostoc 78-12A. Journal of Natural Product 2005; 68: 1793-1795.

60. Zheng CJ, Yoo J-S, Lee T-G, Cho H-Y, Kim Y-H, Kim W-G. Fatty acid synthesis is a target for antibacterial activity of unsaturated fatty acids. FEBS Letter 2005; 579: 5157-5162.

61. Zelík P, Lukesová A, Voloshko LN, Stys D, Kopecký J. Screening for acetylcholinesterase inhibitory activity in cyanobacteria of the genus Nostoc. Journal of Enzyme Inhibition Medicinal Chemistry 2009; 24(2): 531-536.

62. Choi H, Oh SK, Yih W, Chin J, Kang H, Rho JR (2008) Cyanopeptoline CB071: a cyclic depsipeptide isolated from the freshwater cyanobacterium Aphanocapsa sp. Chem Pharm Bull (Tokyo) 56: 1191-1193.

63. Rodríguez-Meizoso I, Jaime L, Santoyo S, Cifuentes A, García-Blairsy Reina G, Señoráns FJ, Ibáñez E. Pressurized fluid extraction of bioactive compounds from Phormidium species. Journal of Agricultural Food Chemistry 2008;28;56(10): 3517-3523 .

64. Kwan JC, Rocca JR, Abboud KA, Paul VJ, Luesch H. Total Structure Determination of Grassypeptolide, a New Marine Cyanobacterial Cytotoxin. Organic Letter 2008; 10 (5): 789-792.

65. Teruya T, Sasaki H, Fukazawa H, Suenaga K. Bisebromamide, a potent cytotoxic peptide from the marine cyanobacterium Lyngbya sp.: isolation, stereostructure, and biological activity. Organic Letter 2009; 11: 5062-5065.

66. Balunas MJ, Grosso MF, Villa FA, Engene N, McPhail KL, Tidgewell K, Pineda LM, Gerwick L, Spadafora C, Kyle DE, Gerwick WH. Coibacins A_D, Antileishmanial Marine Cyanobacterial Polyketides with Intriguing Biosynthetic Origins. Org Lett 2012; 14: 3878- 3881.

67. Kang H, Santarsiero BD, Kim H, Krunic A, Shen Q, Swanson SM, Chai H, Kinghorn AD, Orjala J. Merocyclophanes A and B, antiproliferative cyclophanes from the cultured terrestrial Cyanobacterium Nostoc sp. Phytochemistry 2012; 79: 109–115.
Statistics
601 Views | 809 Downloads
How to Cite
Kumar, M. “HARVESTING OF VALUABLE ENO- AND EXO-METABOLITES FORM CYANOBACTERIA: A POTENTIAL SOURCE”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 7, no. 2, Apr. 2014, pp. 24-28, https://innovareacademics.in/journals/index.php/ajpcr/article/view/858.
Section
Articles